text:
Are you Sinil Kim?Claim your profile
Publications (26)331.5 Total impact
Article: Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma[Show abstract] [Hide abstract]
ABSTRACT: In the phase III AXIS trial, axitinib significantly prolonged progression-free survival (PFS) vs. sorafenib in patients with previously treated metastatic renal cell carcinoma (mRCC). Analyses of associations between germline single-nucleotide polymorphisms (SNPs) and outcomes are reported.Clinical Genitourinary Cancer 02/2015; DOI:10.1016/j.clgc.2015.02.007 · 1.69 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Axitinib, a potent and selective inhibitor of vascular endothelial growth factor receptors, showed antitumor activity as a single agent against several solid tumor types in Phase II and III trials. This study was conducted to evaluate axitinib pharmacokinetics across a variety of solid tumors.Cancer Chemotherapy and Pharmacology 10/2014; DOI:10.1007/s00280-014-2606-6 · 2.57 Impact Factor
Article: Treatment of Advanced Thyroid Cancer With Axitinib: Phase 2 Study With Pharmacokinetic/Pharmacodynamic and Quality-of-Life Assessments[Show abstract] [Hide abstract]
ABSTRACT: BACKGROUND: In a previous phase 2 trial, axitinib was active and well tolerated in patients with advanced thyroid cancer. In this second phase 2 trial, the efficacy and safety of axitinib were evaluated further in this population, and pharmacokinetic/pharmacodynamic relationships and patient-reported outcomes were assessed. METHODS: Patients (N = 52) with metastatic or unresectable, locally advanced medullary or differentiated thyroid cancer that was refractory or not amenable to iodine-131 received a starting dose of axitinib 5 mg twice daily. The primary endpoint was the objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety, pharmacokinetic parameters, and patient-reported outcomes assessed with the MD Anderson Symptom Inventory questionnaire. RESULTS: The overall ORR was 35% (18 partial responses), and 18 patients had stable disease for >= 16 weeks. The median PFS was 16.1 months, and the median OS was 27.2 months. All-causality, grade >= 3 adverse events (>5%) were fatigue, dyspnea, diarrhea, decreased weight, pain in extremity, hypertension, decreased appetite, palmar-plantar erythrodysesthesia, hypocalcemia, and myalgia. Patients who had greater axitinib exposure had a longer median PFS. Quality of life was maintained during treatment with axitinib, and no significant deterioration in symptoms or interference in daily life caused by symptoms, assessed on MD Anderson Symptom Inventory subscales, were observed. CONCLUSIONS: Axitinib has activity and a manageable safety profile while maintaining quality of life, and it represents an additional treatment option for patients with advanced thyroid cancer. (C) 2014 American Cancer Society.Cancer 05/2014; 120(17). DOI:10.1002/cncr.28766 · 5.20 Impact Factor
Article: Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer[Show abstract] [Hide abstract]
ABSTRACT: The efficacy and safety of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 in combination with pemetrexed and cisplatin was evaluated in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). Overall, 170 patients were randomly assigned to receive axitinib at a starting dose of 5-mg twice daily continuously plus pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of up to six 21-day cycles (arm I); axitinib on days 2 through 19 of each cycle plus pemetrexed/cisplatin (arm II); or pemetrexed/cisplatin alone (arm III). The primary endpoint was progression-free survival (PFS). Median PFS was 8.0, 7.9, and 7.1 months in arms I, II, and III, respectively (hazard ratio: arms I vs. III, 0.89 [P = 0.36] and arms II vs. III, 1.02 [P = 0.54]). Median overall survival was 17.0 months (arm I), 14.7 months (arm II), and 15.9 months (arm III). Objective response rates (ORRs) for axitinib-containing arms were 45.5% (arm I) and 39.7% (arm II) compared with 26.3% for pemetrexed/cisplatin alone (arm III). Gastrointestinal disorders and fatigue were frequently reported across all treatment arms. The most common all-causality grade >=3 adverse events were hypertension in axitinib-containing arms (20% and 17%, arms I and II, respectively) and fatigue with pemetrexed/cisplatin alone (16%). Axitinib in combination with pemetrexed/cisplatin was generally well tolerated. Axitinib combinations resulted in non-significant differences in PFS and numerically higher ORR compared with chemotherapy alone in advanced NSCLC.Trial registration: ClinicalTrials.gov: NCT00768755 (October 7, 2008).BMC Cancer 04/2014; 14(1):290. DOI:10.1186/1471-2407-14-290 · 3.32 Impact FactorThis article is viewable in ResearchGate's enriched formatRG Format enables you to read in context with side-by-side figures, citations, and feedback from experts in your field.
Article: Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.[Show abstract] [Hide abstract]
ABSTRACT: Inhibitors of the vascular endothelial growth factor (VEGF) pathway frequently induce hypertension when used to treat patients with advanced renal cell carcinoma (RCC). This analysis characterizes hypertension and hypertension-related events in patients treated with the VEGF pathway inhibitors axitinib or sorafenib in the AXIS trial. AXIS was a randomized phase III study of axitinib versus sorafenib in patients with metastatic RCC following failure of one prior systemic regimen. Patients with uncontrolled hypertension were excluded, but patients with hypertension controlled with antihypertensive medication were allowed to participate. Guidelines for hypertension management included adjustment or addition of antihypertensive medications and/or axitinib or sorafenib dose reductions, interruptions, or discontinuations. Treatment-emergent all-causality hypertension occurred in 145 (40.4 %) axitinib-treated patients (N = 359) and 103 (29.0 %) sorafenib-treated patients (N = 355), with grade 3 hypertension reported in 55 (15.3 %) and 38 (10.7 %) patients, respectively, and grade 4 hypertension reported in one (0.3 %) patient in each arm. Hypertension-related events led to axitinib dose interruptions (n = 46; 12.8 %), dose reductions (n = 16; 4.5 %), or discontinuations (n = 1; 0.3 %). Approximately 50 % of axitinib-treated patients with grade 3 or 4 hypertension continued treatment for ≥ 9 months. Hypertension-related sequelae occurred in <1 % of axitinib-treated patients. Hypertension was more frequently observed during treatment with axitinib than sorafenib in patients with RCC, but axitinib-induced hypertension rarely led to treatment discontinuation or cardiovascular sequelae. Recommendations for monitoring blood pressure and managing hypertension during axitinib therapy are presented.Targeted Oncology 03/2014; DOI:10.1007/s11523-014-0307-z · 3.46 Impact Factor
Article: Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study.[Show abstract] [Hide abstract]
ABSTRACT: Axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, shows activity in multiple tumor types, including those refractory to previous antiangiogenic therapy. This randomized, multicenter, parallel-group, open-label phase II trial compared axitinib with bevacizumab each in combination with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) for second-line treatment of metastatic colorectal cancer. Patients were randomized 1:1 to axitinib 5 mg twice daily or bevacizumab 5 mg/kg every 2 weeks plus modified FOLFOX-6 (if previously treated with irinotecan) or FOLFIRI (if previously treated with oxaliplatin) and were stratified by performance status and prior bevacizumab therapy. Primary endpoint was progression-free survival. In 171 patients, progression-free survival was 7.6 months with axitinib/FOLFOX vs. 6.4 months with bevacizumab/FOLFOX (hazard ratio [HR], 1.04; 95% confidence interval [CI], 0.55-1.96; 1-sided P = .55) and 5.7 months with axitinib/FOLFIRI vs. 6.9 months with bevacizumab/FOLFIRI (HR, 1.27; 95% CI, 0.77-2.11; 1-sided P = .83). Overall survival was 17.1 vs. 14.1 months with axitinib/FOLFOX and bevacizumab/FOLFOX (HR, 0.69; 95% CI, 0.37-1.27; 1-sided P = .12) and 12.9 vs. 15.7 months with axitinib/FOLFIRI and bevacizumab/FOLFIRI (HR, 1.36; 95% CI, 0.82-2.24; 1-sided P = .88). More grade ≥ 3 adverse events (eg, diarrhea, fatigue, decreased appetite) and treatment discontinuations due to adverse events occurred with axitinib. Compared with bevacizumab, axitinib did not improve outcomes when added to second-line chemotherapy for metastatic colorectal cancer. With current dosing regimens, axitinib plus FOLFOX or FOLFIRI seems to be less well tolerated than bevacizumab-based regimens.Clinical Colorectal Cancer 12/2013; 12(4):239-47. DOI:10.1016/j.clcc.2013.09.001 · 2.91 Impact Factor
Article: Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.[Show abstract] [Hide abstract]
ABSTRACT: In previous clinical trials of patients with metastatic renal-cell carcinoma, patients treated with axitinib as second-line therapy had longer median progression-free survival than those treated with sorafenib. We therefore undertook a phase 3 trial comparing axitinib with sorafenib in patients with treatment-naive metastatic renal-cell carcinoma. In this randomised, open-label, phase 3 trial, patients with treatment-naive, measurable, clear-cell metastatic renal-cell carcinoma from 13 countries were stratified by Eastern Cooperative Oncology Group performance status, and then randomly assigned (2:1) by a centralised registration system to receive axitinib 5 mg twice daily, or sorafenib 400 mg twice daily. The primary endpoint was progression-free survival, assessed by masked independent review committee in the intention-to-treat population. This ongoing trial is registered at ClinicalTrials.gov, NCT00920816. Between June 14, 2010, and April 21, 2011, we randomly assigned 192 patients to receive axitinib, and 96 patients to receive sorafenib. The cutoff date for this analysis was July 27, 2012, when 171 (59%) of 288 patients died or had disease progression, as assessed by the independent review committee. There was no significant difference in median progression-free survival between patients treated with axitinib or sorafenib (10·1 months [95% CI 7·2-12·1] vs 6·5 months [4·7-8·3], respectively; stratified hazard ratio 0·77, 95% CI 0·56-1·05). Any-grade adverse events that were more common (≥10% difference) with axitinib than with sorafenib were diarrhoea (94 [50%] of 189 patients vs 38 [40%] of 96 patients), hypertension (92 [49%] vs 28 [29%]), weight decrease (69 [37%] vs 23 [24%]), decreased appetite (54 [29%] vs 18 [19%]), dysphonia (44 [23%] vs ten [10%]), hypothyroidism (39 [21%] vs seven [7%]), and upper abdominal pain (31 [16%] vs six [6%]); those more common with sorafenib than with axitinib included palmar-plantar erythrodysaesthesia (PPE; 37 [39%] of 96 patients vs 50 [26%] of 189), rash (19 [20%] vs 18 [10%]), alopecia (18 [19%] vs eight [4%]), and erythema (18 [19%] vs five [3%]). The most common grade 3 or 4 adverse events in patients treated with axitinib included hypertension (26 [14%] of 189 patients), diarrhoea (17 [9%]), asthenia (16 [8%]), weight decrease (16 [8%]), and PPE (14 [7%]); common grade 3 or 4 adverse events in patients treated with sorafenib included PPE (15 [16%] of 96 patients), diarrhoea (five [5%]), and asthenia (five [5%]). Serious adverse events were reported in 64 (34%) of 189 patients receiving axitinib, and 24 (25%) of 96 patients receiving sorafenib. Axitinib did not significantly increase progression-free survival in patients with treatment-naive metastatic renal-cell carcinoma compared with those treated with sorafenib, but did demonstrate clinical activity and an acceptable safety profile. Pfizer Inc.The Lancet Oncology 10/2013; DOI:10.1016/S1470-2045(13)70465-0 · 25.12 Impact Factor
Article: Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.[Show abstract] [Hide abstract]
ABSTRACT: Population pharmacokinetic data suggest axitinib plasma exposure correlates with efficacy in metastatic renal-cell carcinoma. Axitinib dose titration might optimise exposure and improve outcomes. We prospectively assessed the efficacy and safety of axitinib dose titration in previously untreated patients with metastatic renal-cell carcinoma. In this randomised, double-blind, multicentre, phase 2 study, patients were enrolled from 49 hospitals and outpatient clinics in the Czech Republic, Germany, Japan, Russia, Spain, and USA. Patients with treatment-naive metastatic renal-cell carcinoma received axitinib 5 mg twice daily during a 4 week lead-in period. Those patients with blood pressure 150/90 mm Hg or lower, no grade 3 or 4 treatment-related toxic effects, no dose reductions, and no more than two antihypertensive drugs for 2 consecutive weeks were stratified by Eastern Cooperative Oncology Group performance status (0 vs 1), and then randomly assigned (1:1) to either masked titration with axitinib to total twice daily doses of 7 mg, and then 10 mg, if tolerated, or placebo titration. Patients who did not meet these criteria continued without titration. The primary objective was comparison of the proportion of patients achieving an objective response between randomised groups. Safety analyses were based on all patients who received at least one dose of axitinib. This ongoing trial is registered with ClinicalTrials.gov, number NCT00835978. Between Sept 2, 2009, and Feb 28, 2011, we enrolled 213 patients, of whom 112 were randomly assigned to either the axitinib titration group (56 patients) or the placebo titration group (56 patients). 91 were not eligible for titration, and ten withdrew during the lead-in period. 30 patients (54%, 95% CI 40-67) in the axitinib titration group had an objective response, as did 19 patients (34%, 22-48]) in the placebo titration group (one-sided p=0·019). 54 (59%, 95% CI 49-70) of non-randomised patients achieved an objective response. Common grade 3 or worse, all-causality adverse events in treated patients were hypertension (ten [18%] of 56 in the axitinib titration group vs five [9%] of 56 in the placebo titration group vs 45 [49%] of 91 in the non-randomised group), diarrhoea (seven [13%] vs two [4%] vs eight [9%]), and decreased weight (four [7%] vs three [5%] vs six [7%]). One or more all-causality serious adverse events were reported in 15 (27%) patients in the axitinib titration group, 13 (23%) patients in the placebo titration group, and 35 (38%) non-randomised patients. The most common serious adverse events in all 213 patients were disease progression and dehydration (eight each [4%]), and diarrhoea, vomiting, pneumonia, and decreased appetite (four each [2%]). The greater proportion of patients in the axitinib titration group achieving an objective response supports the concept of individual axitinib dose titration in selected patients with metastatic renal-cell carcinoma. Axitinib shows clinical activity with a manageable safety profile in treatment-naive patients with this disease. Pfizer Inc.The Lancet Oncology 10/2013; DOI:10.1016/S1470-2045(13)70464-9 · 25.12 Impact Factor
Article: Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis[Show abstract] [Hide abstract]
ABSTRACT: Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, approved for second-line therapy for advanced renal cell carcinoma (RCC). Axitinib population pharmacokinetic and pharmacokinetic/pharmacodynamic relationships were evaluated. Using nonlinear mixed effects modeling with pooled data from 383 healthy volunteers, 181 patients with metastatic RCC, and 26 patients with other solid tumors in 17 trials, the disposition of axitinib was best described by a 2-compartment model with first-order absorption and a lag time, with estimated mean systemic clearance (CL) of 14.6 L/h and central volume of distribution (Vc ) of 47.3 L. Of 12 covariates tested, age over 60 years and Japanese ethnicity were associated with decreased CL, whereas Vc increased with body weight. However, the magnitude of predicted changes in exposure based on these covariates does not warrant dose adjustments. Multivariate Cox proportional hazard regression and logistic regression analyses showed that higher exposure and diastolic blood pressure were independently associated with longer progression-free and overall survivals and higher probability of partial response in metastatic RCC patients. These findings support axitinib dose titration to increase plasma exposure in patients who tolerate axitinib, and also demonstrate diastolic blood pressure as a potential marker of efficacy.The Journal of Clinical Pharmacology 05/2013; 53(5). DOI:10.1002/jcph.73 · 2.47 Impact Factor
Article: Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial[Show abstract] [Hide abstract]
ABSTRACT: OBJECTIVE: Axitinib is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2 and 3. The efficacy and safety of axitinib in Japanese patients with metastatic renal cell carcinoma were evaluated. METHODS: A subgroup analysis was conducted in Japanese patients enrolled in the randomized Phase III trial of axitinib versus sorafenib after failure of one prior systemic therapy for metastatic renal cell carcinoma. RESULTS: Twenty-five (of 361) and 29 (of 362) patients randomized to the axitinib and sorafenib arms, respectively, were Japanese and included in this analysis. Median progression-free survival in Japanese patients was 12.1 months (95% confidence interval 8.6 to not estimable) for axitinib and 4.9 months (95% confidence interval 2.8-6.6) for sorafenib (hazard ratio 0.390; 95% confidence interval 0.130-1.173; stratified one-sided P = 0.0401). The objective response rate was 52.0% for axitinib and 3.4% for sorafenib (P = 0.0001). The common all-causality adverse events (all grades) in Japanese patients were dysphonia (68%), hypertension (64%), hand-foot syndrome (64%) and diarrhea (56%) for axitinib, and hand-foot syndrome (86%), hypertension (62%) and diarrhea (52%) for sorafenib. The safety profiles of axitinib and sorafenib in Japanese patients were generally similar to those observed in the overall population, with the exceptions of higher incidences of hypertension, dysphonia, hand-foot syndrome, hypothyroidism and stomatitis. CONCLUSIONS: Axitinib is efficacious and well tolerated in Japanese patients with previously treated metastatic renal cell carcinoma, consistent with the results in the overall population, providing a new targeted therapy for these Japanese patients.Japanese Journal of Clinical Oncology 04/2013; 43(6). DOI:10.1093/jjco/hyt054 · 1.75 Impact FactorThis article is viewable in ResearchGate's enriched formatRG Format enables you to read in context with side-by-side figures, citations, and feedback from experts in your field.
Article: Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study[Show abstract] [Hide abstract]
ABSTRACT: BACKGROUND: In this multicenter, open-label, randomized phase 2 trial, the authors evaluated the vascular endothelial growth factor receptor inhibitor axitinib, bevacizumab, or both in combination with chemotherapy as first-line treatment of metastatic colorectal cancer (mCRC). METHODS: Patients with previously untreated mCRC were randomized 1:1:1 to receive continuous axitinib 5 mg twice daily, bevacizumab 5 mg/kg every 2 weeks, or axitinib 5 mg twice daily plus bevacizumab 2 mg/kg every 2 weeks, each in combination with modified 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX-6). The primary endpoint was the objective response rate (ORR). RESULTS: In all, 126 patients were enrolled from August 2007 to September 2008. The ORR was numerically inferior in the axitinib arm (n = 42) versus the bevacizumab arm (n = 43; 28.6% vs 48.8%; 1-sided P = .97). Progression-free survival (PFS) (11.0 months vs 15.9 months; 1-sided P = .57) and overall survival (OS) (18.1 months vs 21.6 months; 1-sided P = .69) also were numerically inferior in the axitinib arm. Similarly, efficacy endpoints for the axitinib/bevacizumab arm (n = 41) were numerically inferior (ORR, 39%; PFS, 12.5 months; OS, 19.7 months). The patients who received axitinib had fewer treatment cycles compared with other arms. Common all-grade adverse events across all 3 treatment arms were fatigue, diarrhea, and nausea (all ≥49%). Hypertension and headache were more frequent in the patients who received axitinib. Patients in the bevacizumab arm had the longest treatment exposures and the highest rates of peripheral neuropathy. CONCLUSIONS: Neither the addition of continuous axitinib nor the axitinib/bevacizumab combination to FOLFOX-6 improved ORR, PFS, or OS compared with bevacizumab as first-line treatment of mCRC. Cancer 2013. © 2013 American Cancer Society.Cancer 04/2013; 119(14). DOI:10.1002/cncr.28112 · 5.20 Impact Factor
Article: Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.[Show abstract] [Hide abstract]
ABSTRACT: BACKGROUND: In a phase 3 trial comparing the efficacy and safety of axitinib versus sorafenib as second-line treatment for metastatic renal cell carcinoma, patients given axitinib had a longer progression-free survival (PFS). Here, we report overall survival and updated efficacy, quality of life, and safety results. METHODS: Eligible patients had clear cell metastatic renal cell carcinoma, progressive disease after one approved systemic treatment, and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1. 723 patients were stratified by ECOG PS and previous treatment and randomly allocated (1:1) to receive axitinib (5 mg twice daily; n=361) or sorafenib (400 mg twice daily; n=362). The primary endpoint was PFS assessed by a masked, independent radiology review committee. We assessed patient-reported outcomes using validated questionnaires. Baseline characteristics and development of hypertension on treatment were studied as prognostic factors. Efficacy was assessed in the intention-to-treat population, and safety was assessed in patients who received at least one dose of the study drug. This ongoing trial is registered on ClinicalTrials.gov, number NCT00678392. FINDINGS: Median overall survival was 20·1 months (95% CI 16·7-23·4) with axitinib and 19·2 months (17·5-22·3) with sorafenib (hazard ratio [HR] 0·969, 95% CI 0·800-1·174; one-sided p=0·3744). Median investigator-assessed PFS was 8·3 months (95% CI 6·7-9·2) with axitinib and 5·7 months (4·7-6·5) with sorafenib (HR 0·656, 95% CI 0·552-0·779; one-sided p<0·0001). Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment, but decreased at end-of-treatment. Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients. In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20·7 months (95% CI 18·4-24·6) versus 12·9 months (10·1-20·4) in the axitinib group (p=0·0116), and 20·2 months (17·1-32·0) versus 14·8 months (12·0-17·7) in the sorafenib group (one-sided p=0·0020). INTERPRETATION: Although overall survival, a secondary endpoint for the study, did not differ between the two groups, investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group. These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma. FUNDING: Pfizer Inc.The Lancet Oncology 04/2013; DOI:10.1016/S1470-2045(13)70093-7 · 25.12 Impact Factor
Article: Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Treated With Axitinib[Show abstract] [Hide abstract]
ABSTRACT: BACKGROUND: In a phase II study of axitinib for cytokine-refractory metastatic renal cell carcinoma, median overall survival (OS) was 29.9 months (95% CI, 20.3 to not estimable months). PATIENTS AND METHODS: Long-term survival data were collected retrospectively from 52 patients with cytokine-refractory metastatic renal cell carcinoma who received axitinib in a completed phase II study (protocol 1), 11 of whom enrolled in a continuing access protocol (protocol 2), for the current observational study (protocol 3). In a post hoc analysis, the patients were grouped into quartiles based on cycle 1 day 1, 1- to 2-hour post-dose axitinib plasma levels to explore the impact of drug exposure on efficacy. RESULTS: The 5-year survival rate was 20.6% (95% CI, 10.9%-32.4%), with a median follow-up of 5.9 years. Frequent all-grade adverse events were fatigue (n = 38; 73.1%), diarrhea (n = 34; 65.4%), hypertension (n = 33; 63.5%), and nausea (n = 33; 63.5%). Quartile 3 patients (axitinib level, 45.2-56.4 ng/mL; n = 12) had the best clinical outcome: objective response rate 82%, median progression-free survival (PFS) 28.3 months, and median OS that was not reached after 5 years. CONCLUSIONS: Axitinib was well tolerated and provided an estimated 5-year survival rate of 20.6% for cytokine-refractory metastatic renal cell carcinoma. Exploratory analyses showed numerically higher objective response rate and longer OS and PFS in patients who achieved post-first-dose axitinib plasma concentrations within a specific range.Clinical Genitourinary Cancer 02/2013; 11(2). DOI:10.1016/j.clgc.2012.12.004 · 1.69 Impact Factor
Article: Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma[Show abstract] [Hide abstract]
ABSTRACT: This multicenter, open-label, phase II study evaluated the safety and clinical activity of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, 2, and 3, in patients with metastatic melanoma. Thirty-two patients with a maximum of one prior systemic therapy received axitinib at a starting dose of 5 mg twice daily. The primary endpoint was objective response rate. Objective response rate was 18.8% [95% confidence interval (CI), 7.2-36.4], comprising one complete and five partial responses with a median response duration of 5.9 months (95% CI, 5.0-17.0). Stable disease at 16 weeks was noted in six patients (18.8%), with an overall clinical benefit rate of 37.5%. Six-month progression-free survival rate was 33.9%, 1-year overall survival rate was 28.1%, and median overall survival was 6.6 months (95% CI, 5.2-9.0). The most frequently (>15%) reported nonhematologic, treatment-related adverse events were fatigue, hypertension, hoarseness, and diarrhea. Treatment-related fatal bowel perforation, a known class effect, occurred in one patient. Axitinib selectively decreased plasma concentrations of soluble VEGFR (sVEGFR)-2 and sVEGFR-3 compared with soluble stem cell factor receptor (sKIT). No significant association was noted between plasma levels of axitinib and response. However, post hoc analyses indicated potential relationships between efficacy endpoints and diastolic blood pressure of 90 mm Hg or higher as well as baseline serum lactate dehydrogenase levels. Axitinib was well tolerated, showed a selective VEGFR-inhibitory profile, and showed single-agent activity in metastatic melanoma. Further evaluations of axitinib, alone and combined with chemotherapy, are ongoing.Clinical Cancer Research 12/2011; 17(23):7462-9. DOI:10.1158/1078-0432.CCR-11-0534 · 8.19 Impact Factor
Article: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial[Show abstract] [Hide abstract]
ABSTRACT: The treatment of advanced renal cell carcinoma has been revolutionised by targeted therapy with drugs that block angiogenesis. So far, no phase 3 randomised trials comparing the effectiveness of one targeted agent against another have been reported. We did a randomised phase 3 study comparing axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor (VEGF) receptors, with sorafenib, an approved VEGF receptor inhibitor, as second-line therapy in patients with metastatic renal cell cancer. We included patients coming from 175 sites (hospitals and outpatient clinics) in 22 countries aged 18 years or older with confirmed renal clear-cell carcinoma who progressed despite first-line therapy containing sunitinib, bevacizumab plus interferon-alfa, temsirolimus, or cytokines. Patients were stratified according to Eastern Cooperative Oncology Group performance status and type of previous treatment and then randomly assigned (1:1) to either axitinib (5 mg twice daily) or sorafenib (400 mg twice daily). Axitinib dose increases to 7 mg and then to 10 mg, twice daily, were allowed for those patients without hypertension or adverse reactions above grade 2. Participants were not masked to study treatment. The primary endpoint was progression-free survival (PFS) and was assessed by a masked, independent radiology review and analysed by intention to treat. This trial was registered on ClinicalTrials.gov, number NCT00678392. A total of 723 patients were enrolled and randomly assigned to receive axitinib (n=361) or sorafenib (n=362). The median PFS was 6·7 months with axitinib compared to 4·7 months with sorafenib (hazard ratio 0·665; 95% CI 0·544-0·812; one-sided p<0·0001). Treatment was discontinued because of toxic effects in 14 (4%) of 359 patients treated with axitinib and 29 (8%) of 355 patients treated with sorafenib. The most common adverse events were diarrhoea, hypertension, and fatigue in the axitinib arm, and diarrhoea, palmar-plantar erythrodysaesthesia, and alopecia in the sorafenib arm. Axitinib resulted in significantly longer PFS compared with sorafenib. Axitinib is a treatment option for second-line therapy of advanced renal cell carcinoma. Pfizer Inc.The Lancet 11/2011; 378(9807):1931-9. DOI:10.1016/S0140-6736(11)61613-9 · 39.21 Impact Factor
Article: Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer[Show abstract] [Hide abstract]
ABSTRACT: This multicenter, randomized, double-blind, phase II study assessed safety and efficacy of axitinib plus docetaxel in metastatic breast cancer (MBC). Women with MBC were randomly assigned 2:1 to receive docetaxel 80 mg/m2 once every 3 weeks plus axitinib 5 mg twice per day (combination arm) or placebo (placebo arm), following a lead-in phase I trial. The primary end point was time to progression (TTP). In all, 168 patients were enrolled; 112 were randomly assigned to axitinib and 56 to placebo. Median TTP was numerically longer in the combination arm than in the placebo arm (8.1 v 7.1 months), but this difference was not statistically significant (hazard ratio, 1.24; 95% CI, 0.82 to 1.87; one-sided P = .156). The difference in median TTP was greatest among patients who had received prior adjuvant chemotherapy (9.2 v 7.0 months; P = .043, prespecified subgroup analysis). Objective response rate was higher in the combination arm (41.1% v 23.6%; P = .011). The most common grades 3 to 4 treatment-related adverse events (combination/placebo) included diarrhea (10.8%/0%), fatigue (10.8%/5.4%), stomatitis (12.6%/1.8%), mucositis (9.0%/0%), asthenia (7.2%/0%), and hypertension (4.5%/0%). Three patients in the combination arm experienced serious thromboembolic events (one death). Febrile neutropenia was more frequent in the combination arm (15.3% v 7.1%); rates of other hematologic toxicities were comparable. Increased toxicity with axitinib was generally managed by dose reduction and/or growth factor support. The addition of axitinib to docetaxel did not improve TTP in first-line MBC treatment. Combination therapy may be more effective in patients previously exposed to adjuvant chemotherapy.Journal of Clinical Oncology 06/2011; 29(18):2459-65. DOI:10.1200/JCO.2010.31.2975 · 17.88 Impact Factor
Article: Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer.[Show abstract] [Hide abstract]
ABSTRACT: Axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3, is under investigation for treatment of various solid tumors. The safety and pharmacokinetics of axitinib in combination with gemcitabine in patients with advanced pancreatic cancer was evaluated in the phase I portion of this trial. The randomized phase II portion was reported separately. Patients with advanced pancreatic cancer who had received no prior chemotherapy were eligible for this study. Pharmacokinetic profiles of the drugs were obtained on cycle (C) 1 day (D) 1 (gemcitabine alone 1,000 mg/m(2)), C1D14 (steady state, axitinib alone 5 mg twice daily [BID]), and C1D15 (gemcitabine plus steady-state axitinib). Adverse events were monitored weekly at the clinic. Eight patients participated in the phase IB portion of the trial. Patients received gemcitabine on D1, D8, and D15 and continuous axitinib in a 28 day-cycle beginning C1D3. There was no dose-limiting toxicity. Common treatment-related adverse events included fatigue, diarrhea, dysphonia, and hypertension. Myelosuppression was similar to gemcitabine monotherapy. No apparent major pharmacokinetic interactions between gemcitabine and axitinib were observed. Of six patients evaluable for efficacy, three had confirmed partial responses. Axitinib (5 mg BID) and gemcitabine (1,000 mg/m(2)) were well tolerated when administered together, without any pharmacokinetic interactions, and showed encouraging antitumor activity.Investigational New Drugs 06/2011; 30(4):1531-9. DOI:10.1007/s10637-011-9697-2 · 3.50 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: To evaluate if diastolic blood pressure (dBP) ≥90 mm Hg during axitinib treatment is a marker of efficacy. The relationship between dBP ≥90 mm Hg and efficacy was retrospectively explored across 5 phase II studies of single-agent axitinib for the treatment of 4 different tumor types. All patients had baseline BP ≤140/90 mm Hg and were stratified into 2 groups based on in-clinic BP measurements after initiating therapy: those with dBP <90 mm Hg throughout therapy and those with at least 1 dBP ≥90 mm Hg. Median overall survival (mOS), median progression-free survival (mPFS), objective response rate (ORR), and adverse events were evaluated by dBP group in individual and pooled analyses. Two-hundred thirty patients were evaluated. Patients with dBP ≥90 mm Hg had a significantly lower relative risk of death than those with dBP <90 mm Hg [adjusted HR (95% CI) = 0.55 (0.39, 0.77); P < 0.001]. The relative risk of progression was also lower in patients with dBP ≥90 mm Hg [HR (95% CI) = 0.76 (0.54, 1.06), P = 0.107], and ORR was significantly higher (43.9% vs. 12.0%; P < 0.001). In an 8-week landmark analysis, mOS (25.8 vs. 14.9 months) and mPFS (10.2 vs. 7.1 months) were greater for patients in the ≥90 mm Hg group. Adverse events were similar between groups. Axitinib efficacy correlated with dBP ≥90 mm Hg. Further investigation of dBP as a predictive biomarker of efficacy in patients receiving axitinib is warranted.Clinical Cancer Research 06/2011; 17(11):3841-9. DOI:10.1158/1078-0432.CCR-10-2806 · 8.19 Impact Factor
Article: Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.[Show abstract] [Hide abstract]
ABSTRACT: The goal of the study was to determine the relationship of baseline Functional Assessment of Cancer Therapy-Kidney Cancer Symptom Index (FKSI) scores with median progression-free survival (mPFS) and median overall survival (mOS) after treatment with axitinib in patients with sorafenib-refractory metastatic renal cell carcinoma. As part of a multicenter, open-label, phase II study, patients (N = 62) reported symptoms at baseline using the FKSI, with higher scores indicating less severe symptoms. A Weibull (fully parametric) model was fit to time-to-event data to establish the relationship of baseline FKSI score with mPFS and mOS. Kaplan-Meier curves were obtained as sensitivity analyses. Longer progression-free and overall survivals were associated with higher (more favorable) baseline FKSI-15 and FKSI disease-related symptoms (FKSI-DRS) subscale specific to kidney cancer scores. For example, for FKSI-15 scores of 0 (most symptoms), 30, and 60 (no symptoms), the mPFS were 0.72, 3.83, and 20.43 months, respectively, and the mOS were 1.05, 6.27, and 37.53 months. Similar patterns and interpretations were observed for the FKSI-DRS scores. The results from the Kaplan-Meier analyses supported the parametric model. Baseline patient-reported kidney cancer symptoms are linked to mPFS and mOS in a clear and interpretable way. These results support the evaluation of patient-reported symptoms at baseline in clinical trials and in clinical practice to measure symptom severity and potentially predict progression-free and overall survival outcomes. The results provide a heightened opportunity to use patient data not only to assist in medical treatment planning but also to prepare patients, who have advanced disease and an already reduced expected lifespan, with an opportunity to deal with the psychosocial aspects of the dying process.Journal of Cancer Survivorship 04/2011; 5(3):255-62. DOI:10.1007/s11764-011-0178-6 · 3.57 Impact Factor
Article: Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.[Show abstract] [Hide abstract]
ABSTRACT: Axitinib is a potent, selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3. A randomised phase 2 trial of gemcitabine with or without axitinib in advanced pancreatic cancer suggested increased overall survival in axitinib-treated patients. On the basis of these results, we aimed to assess the effect of treatment with gemcitabine plus axitinib on overall survival in a phase 3 trial. In this double-blind, placebo-controlled, phase 3 study, eligible patients had metastatic or locally advanced pancreatic adenocarcinoma, no uncontrolled hypertension or venous thrombosis, and Eastern Cooperative Oncology Group performance status 0 or 1. Patients, stratified by disease extent (metastatic vs locally advanced), were randomly assigned (1:1) to receive gemcitabine 1000 mg/m(2) intravenously on days 1, 8, and 15 every 28 days plus either axitinib or placebo. Axitinib or placebo were administered orally with food at a starting dose of 5 mg twice a day, which could be dose-titrated up to 10 mg twice daily if well tolerated. A centralised randomisation procedure was used to assign patients to each treatment group, with randomised permuted blocks within strata. Patients, investigators, and the trial sponsor were masked to treatment assignments. The primary endpoint was overall survival. All efficacy analyses were done in all patients assigned to treatment groups for whom data were available; safety and treatment administration and compliance assessments were based on treatment received. This study is registered at ClinicalTrials.gov, number NCT00471146. Between July 27, 2007, and Oct 31, 2008, 632 patients were enrolled and assigned to treatment groups (316 axitinib, 316 placebo). At an interim analysis in January, 2009, the independent data monitoring committee concluded that the futility boundary had been crossed. Median overall survival was 8·5 months (95% CI 6·9-9·5) for gemcitabine plus axitinib (n=314, data missing for two patients) and 8·3 months (6·9-10·3) for gemcitabine plus placebo (n=316; hazard ratio 1·014, 95% CI 0·786-1·309; one-sided p=0·5436). The most common grade 3 or higher adverse events for gemcitabine plus axitinib and gemcitabine plus placebo were hypertension (20 [7%] and 5 [2%] events, respectively), abdominal pain (20 [7%] and 17 [6%]), fatigue (27 [9%] and 21 [7%]), and anorexia (19 [6%] and 11 [4%]). The addition of axitinib to gemcitabine does not improve overall survival in advanced pancreatic cancer. These results add to increasing evidence that targeting of VEGF signalling is an ineffective strategy in this disease. Pfizer.The Lancet Oncology 02/2011; 12(3):256-62. DOI:10.1016/S1470-2045(11)70004-3 · 25.12 Impact Factor
Top Journals
- The Lancet Oncology (5)
- Journal of Clinical Oncology (4)
- Clinical Cancer Research (2)
- Cancer (2)
- The Lancet (2)
Pfizer Inc.New York City, New York, United States


text:
Adele Gets Digital Big Ups, Daft Punk Mashup
Adele keeps on breaking records. Her latest coup has taken her hit single "Rolling In The Deep" all the way to the top of the digital sales charts. Billboard announced it is officially the second biggest selling digital song of all time and the biggest ever by a female artist. This means Adele's track has officially outsold work by Lady Gaga, Katy Perry, Rihanna, Madonna, and a host of other female stars.
[photogallerylink id=37766]
"Rolling In The Deep" has cumulative sales of 6.68 million tracks, trailing behind the Black Eyed Peas who have sold 7.82 million copies of "I Got A Feeling." This knocks Lady Gaga's "Poker Face" to third place with 6.62 million in sales.
San Diego based remixer Carlos Serrano released his mashup of Adele's "Set Fire To The Rain" and Daft Punk's "Something About Us" to the Internet. "Set Fire To The Rain" is currently setting fire to the charts and this mashup offers a soothing, electronic-tinged spin on Adele's latest hit single.
Adele Continues Record Breaking Streak
Adele Fools Us All, Heading Back Into Studio!
Artists Covering Other Artists: The Many Reinventions of a Pop Song
Read More On Fresh1027.com:
- Ed Sheeran Gives Newly Married Couple Surprise of a Lifetime at Their Wedding: Watch
- Here's Billy Zane Reading Tweets Meant for Zayn Malik
- Duran Duran's New Album Features Nile Rodgers, John Frusciante, Mark Ronson Collabs
- Zayn Malik Breaks Silence About Quitting One Direction, Plans Solo Career (Eventually)
- Jimmy Fallon Singing 'Barbara Ann' with Wax Statues of Himself Is a Little Creepy
- Gene Simmons is Making a Horror Movie with the WWE
[photogallerylink id=73661]
[photogallerylink id=72621]

subset: commoncrawl


text:
2011 Houghton Stripe Range Cabernet Sauvignon
12 x 750 ml Bottles | RRP: $15.00 $15.00 | Cracka Rating: 4/53
Producer: Houghton Type: Red Varietal: Cabernet Sauvignon Region: Swan District, WA
But we do have...
2011 Forest Hill Vineyard Estate Cabernet Sauvignon
2011 Forest Hill Vineyard Estate Cabernet Sauvignon
Our Price: $26.99 /Bottle
Sold in cases of 12 bottles (750 ml)
Case Price: $323.88
Case Price: $323.88
- The stripe range from Houghton has been a reliable favourite with Aussies for years. Many a gen X and Y probably popped their wine cherry with Houghton, and it still continues to be a 'go to' wine at a value price. Vibrant in colour, aromas of red berried, cherry and plummy fruits lift from the glass, along with a hint of minty freshness and red pepper. The palate is supple, soft and juicy with a raspberry centre, fine tannins, and a lick of spice on the finish. It's a value plus wine that is made for sharing. 80
Brilliant and bright garnet in colour with a ruby red hue, the wine displays
intense aromas of raspberry, cherry and plum fruit complemented by black
olive and hints of tomato leaf, mint and red capsicum. The juicy palate is
full of vibrant raspberry, blueberry and cherry fruits combined with
chocolate, cinnamon and clove spice. The tannin structure is soft and
supple providing an excellent example of Western Australian cabernet.
Houghton Awards and AccoladesTop Gold Medal and 96/100, 2012 Royal Melbourne Wine Show
James Halliday says:"
Great value, on a par with that of Houghton Margaret River Cabernet of the same vintage, the latter a better wine, but naturally more expensive; here fragrant and breezy cassis is woven through with fine tannins on the light- to medium-bodied palate, and a touch of oak also appears. Great early drinking 'luncheon claret'.91
Tyson Stelzer says:"
Varietal credentials are on full parade in this value-for-money lunchtime cabernet. Flavours of crunchy blackcurrants and violet perfume carry long through a refreshingly medium-bodied palate of tangy acidity and fine-boned tannins.
Best Drinking: 2013-2016Wine Taste Special Edition 100 - Hall of Honour90


text:
Always Write, Darcy Naybo
Canada Online News - Yuppy Puppy Kelowna
Canada Online News - Murphy's Landing, Nakusp BC, Cabin rentals, RV Resort, Travel, Kootenays,
9:46:38 pm EDT PM
Tuesday, 31 Mar 2015
Gonzo Team!
Columnists & Contributors
Darcy Nybo
On My Mind
Power of Words
Crazy Little Thing Called Love
The Great Dog Debate
Attitude of Gratitude
A Matter of Attitude
Middle Aged Dating - Part One
Middle Aged Dating - Part 2
Kauai - chickens anyone?
Middle Aged Dating - Part 3
Middle Aged Dating - Still Single
Julie Frayn
Creatively Yours
Word Vomit
The sexy apostrophe
Subordinate Clauses
Oxford Comma
Writing Soundtrack
Dangling Participles
DSG - Mood
Books as Lovers
Flip the Bird
John Kereiff
The Rock Doctor
Lori Welbourne
On A Brighter Note
Fred Topel
Film & TV
Howard Stern Interview
Johnny Depp Interview - Transcendent
Johnny Depp Interview - Dark Shadows
Cee Lo Green interview
Betty White Interview
Ashton Kutcher Interview
STEVEN SPIELBERG Interview
Angelina Jolie Interview!
Robert Downey Jr Interview
Ryan Donn
What's On
Charlie Hodge
Dean Unger
Barb Murphy
Catherine Frechette
Ripe With Surprises
Jennifer Abel
SEO Guru!
Brad Krauza
Publisher / CEO
Music Festivals for 2014
Salmon Arm Roots & Blues Fest
Roots and Blue Update 2014
Dancin' Barefoot
Interview with Heart's Ann Wilson
Paul Rodgers
Shawn Hook
George Thorogood
Blaze Of Glory
The Flu
Darby Mills
Aerosmith Rocks
The Autumn Portrait
Cowboy Junkies
Mike Wanchic (John Mellencamp)
Fillis Killer
No Sinner
Jeff Neill
Cynthia Leigh-Ann
Men Without Hats
RAINing Beatles
RHCP rocks YYC
Alexandra Kosachukova Babbel
Gorden James Soles4Souls
Nick Gilder and Sweeny Todd
Zombies Locker Break Out
BC Concert Listings
80s Rock Reunion
Mellencamp and Cowboy Junkies
2012 Music Therapy Ride
Feasting in the Vineyard
Dancin' Barefoot Festival
David F. Ross @ Bike Shop
The Zolas are Coming
$11,000,000 Cello = Priceless Evening
Steve Millar BAnd comes to SOEC
Symphony and Syllables with Shane Koyczan
Roots and Blue Update 2014
Rock the Wish
Jann Arden - March 29, 2014
Live Music Reviews
Working the Wentworth Magic
Tribute Trio Rocks
Paul Rodgers
A night with Johnny Reid
BB King
Thorogood Rocks the SOEC
R.O.C.K in the S.O.E.C.
RAIN Review
Mötley Crüe
Bad Company - Great Music
Blue Rodeo at Prospera 2014
Absolutely YES
Steve Miller and Matthew Curry
An Evening with Sarah McLachlan
Doobie Brothers - More Than All Right
Tragically Hip Rock Prospera by Barb Aguiar
John Kereiff
The Rock Doctor
CD Reviews
My Afternoon With
Harpdog Brown
Ra McGuire of Trooper
Bruce Iglauer
Meat Loaf
Music Listings
Roots and Blues Update March 2014
Listings & Directory
The 7th Annual Ugly Jacket Golf Tournamnet!
Golf Listings
Julie Frayn
Teresa Johnston
Jane Eamon
Gordon Kirkland
The 30K Club!
Health & Beauty
Salons & Spas
Changing Face of Beauty
Vital Waters
ORRiginal hair artist - Shannan Orr
Arts & Culture
Go Party 6
WAG a Huge Success
Relics of the Buddha
Symphony BINGO!
Where To Stay
Murphy's Landing - Nakusp
Kamloops Convention Ctr
The Cove Lakeside
Gonzo's Out There!
Featured Out there Articles & Video
Mother Mother Video Interview
Fit For A King Video!
OSO and Opera Kelowna Family Matinee
SoCountry Internet Radio
Food & Drink
Restaurant Reviews
ORA - Kelowna
ORA Kamloops
Sunset Bistro
Blind Angler
Bonita's Bistro
CedarCreek Terrace
Miradoro at Tinhorn Creek
Kettle Valley Plates Now Open
Food and Booze News
Cocktails Anyone?
Expanding into the US
New DOH for Hester
Okanagan Spirits Caesar Night
1950s Tailgate Party Sold Out
Canadian Culinary Championships
Wine and Dine Time 2015! by Darcy Nybo
Canadian Culinary Championships 2015 Winners
DEVOUR Kelowna - Foodie Heaven!
Restaurant Listings
Winery Listings
Feast of Fields 2014
Fab Feast of Fields
Film, TV & Video
Canada Online News | Gonzo Online! Columinist
Columnist - Darcy Nybo
( 2 Articles )
Columnist - Lori Welbourne - On A Brighter Note
( 82 Articles )
Columnist - Jane Eamon
( 3 Articles )
Columnist - Barb Murphy
( 1 Article )
Columnist - Fred Topel
( 3 Articles )
Columnist - Taylor Charron
( 6 Articles )
Columnist - Julie Frayn
( 23 Articles )
Columnist - Bob Gablehouse - The Low Down
( 3 Articles )
Columnist - Ryan Donn
( 14 Articles )
Columnist - Charlie Hodge - HodgePodge
( 49 Articles )
Columnist - Jennifer Abel
( 1 Article )
Columnist - Dean Unger
( 1 Article )
Gonzo's Recent Editions
Honda Celebration of Light participating Countries announcement
The Record Box for Sunday March 29th, 2015
MEGA-DROP - Salmon Arm Roots & Blues Adds 10 More to the Line-Up
On A Brighter Note by Lori Welbourne - It was news to me
The Record Box for Friday, Feb.27th 2015
The record Box for Monday, Feb.23rd 2015 by John The Rock Doctor
DEVOUR Kelowna - a foodie heaven
Gonzo Online Concert News!! Aerosmith is coming to Kelowna!
Canadian Culinary Championships 2015 Winners!
Hip Rocks Prospera - Fully and Completely by Barb Aguiar
Gonzo Entertainment News - Prospera Place and AEG are proud to ANNOUNCE: Counting Crows
GonzoOnline.ca News: Cirque du Soleil presents VAREKAI at the SOEC May 13 - 17
The Record Box for 01-23-15 by John The Rock Doctor
Wine and Dine Time! by Darcy Nybo
© 2008 Gonzo Publishing Inc. All rights reserved.


text:
Superlative Technologies, Inc.
B-408941: Dec 30, 2013
Additional Materials:
- Full Report:
(202) 512-8278
Office of Public Affairs
(202) 512-4800
Superlative Technologies, Inc. (SuprTEK), of Ashburn, Virginia, protests the award of a task order to Phacil, Inc., of Arlington, Virginia, issued by the United States Transportation Command (TRANSCOM) under request for quotations (RFQ) No. HTC711-13-Q-D008 for support services and related project management for the Surface Deployment and Distribution Command's electronic transportation acquisition (ETA) authentication system. The protester, who is the incumbent contractor for this requirement, alleges that the agency relied on a material misrepresentation in evaluating the acceptability of the awardee's quotation, and unreasonably evaluated the awardee's quotation under the technical/staffing and past performance evaluation factors.
We deny the protest.
Mar 25, 2015
- Affolter Contracting Company, Inc.B-410878,B-410878.2
Mar 24, 2015
- Booz Allen Hamilton, Inc.; Leidos Inc.B-410032.4,B-410032.5,B-410032.6
- Visual Connections, LLCB-410777,B-410777.2
Mar 23, 2015
- AeroSage LLCB-410648.2,B-410648.3
- Sigmatech, Inc.B-410933
Mar 20, 2015
- ExecuTech Strategic Consulting, LLC; TRI-COR Industries, Inc.B-410893,B-410893.2,B-410893.3
- Smith and Nephew, Inc.B-410453
Mar 19, 2015
- Hanel Storage Systems, L.P.B-409030.2
Looking for more? Browse all our products here


text:
September 19, 2014
MAP: City hopes to improve Cosmo-Bethel Park
CHART: MU journalism faculty make slightly less than overall average
September 18, 2014
MAP: Gerbes fuel station site
MAP: Biological conditions of Hinkson Creek
September 17, 2014
GRAPHIC: Tobacco purchase age is 21
Columbia to 21. Four states have counties and towns where 21 is the minimum age to purchase tobacco products. A bill in the New Jersey Senate would increase the age of purchase to 21 statewide.
MAP: Shots fired near Gentry Middle School
September 16, 2014
MAP: Local historians try to preserve Boone's Lick Trail
September 12, 2014
MAP: Mizzou Quick Care Clinics
September 11, 2014
MAP: Confirmed cases of enterovirus 68
September 10, 2014
MAP: The fair markets
September 9, 2014
Location of Katy Bridge in Boonville
MAP: Locations of District Wi-Fi routers
September 5, 2014
MAP: Land for bike path in discussion
The Missouri Bike and Pedestrian Federation wants to create The Rock Island Trail, a bike path that would span from Kansas City to St. Louis. The organization is in talks with Ameren Missouri about purchasing 120 miles of land it owns from Windsor to Union. The company will decide whether to sell by the end of the month.
September 4, 2014
Land for bike path in discussion
September 2, 2014
Missouri and other states undergo minimum wage changes in 2014
August 15, 2014
Mo-99 production involves number of steps
July 23, 2014
MAP: Missouri 4th Congressional District
July 22, 2014
MAP: Missouri's 47th House District
July 9, 2014
MAP: Route B bridge demolition detour


text:
To lidi Ferraresi
- Studio apartments
- 2 room apartments
- 3 room apartments
- 4 room apartments
- 2 room villas
- 3 room villas
- 4 room villas
- Apartments with swimming pool
- Villas with swimming pool
- Apartments Residence Terrazze
- Villas Logonovo
- Apartments Il Sole
- Villas Maria Teresa
- Apartments Residence Sirena
- Apartments Bristol
- Villas Marina
To lidi Ferraresi
- Studio apartments
- 2 room apartments
- 3 room apartments
- 4 room apartments
- 2 room villas
- 3 room villas
- 4 room villas
- New constructions
Holiday houses - holiday apartments in Lido di Spina - Lido Estensi
Comacchio lidos, Italian Adriatic Coast ; Sea vacations: rents and sales of villas and apartments for your holiday in Italy, Lidi of Ferrara,
Villas and apartments near to the sea: weekly rents of apartments for your amazing sea holiday on the Adriatic Riviera, Ferrara beaches
Our homes are ideal for all families and for relaxing holidayon the beach.
Villas rental near the beach in a quite position in the middle of the pinewood, with garden, barbecue and parking place.
Rentals Villas with swimming-pool, Lido di Spina. Cheap holidays in our confortable and furnished studio apartments.
Beautiful homes and apartments well equipped with all comfort for rent direct to the sea.
We have always the ideal solution for you! Lido di Spina, Lido degli Estensi and Porto Garibaldi, rentals holiday apartments and holiday homes, on the widest beach of northem Adriatic Coast.
Lido di Spina, the green capital of the Seven Lidi of Ferrara, a few minutes from the entertainment park of Mirabilandia!
Furnished and corfortable holidays apartments to rent for your vacation in Italy, Emilia Romagna, Lido di Spina, Lido degli Estensi, Comacchio on the Adriatic Coast, Delta Po. Wide chose of apartments, villas and apartments in residence with swimming-pool.
Vacantions Comacchio - Lido di Spina- Lido degli Estensi - Italian Adriatic Coast- Emilia Romagna - Italy - summer rentals, vacations
Lido di Spina appartements for rent for your holidays at lidi ferraresi, adriatic coast: rent
Rent for week-end and short-holiday in Adriatic Sea
Booking 1 week-end or a short-holiday, to sea in Lido di Spina or Lido degli Estensi. We have different solutions for the your holiday.We rent apartaments in the best residences an ...
Periodo: 20-12-2014 / 31-10-2015
Prezzo: 76.00 €
Sea holiday Italy, Emilia Romagna - Lido di Spina and Lido degli Estensi. Vacation rental, promotions summer 2015! Discount -30%
Amazing discounts on Adriatic Coast - In Lido di Spina and Lido degli Estensi, moderns and beautiful sea resorts, vacation homes and apartments near to the sea for rent.   ...
Periodo: 31-01-2015 / 01-07-2015
Sea holiday Italy, Emilia Romagna - Lido di Spina and Lido degli Estensi. Vacation rental, promotions summer 2015! Discount -30%
Amazing discounts on Adriatic Coast - In Lido di Spina and Lido degli Estensi, moderns and beautiful sea resorts, vacation homes and apartments near to the sea for rent.   ...
Periodo: 20-11-2014 / 31-10-2015
Great rates for your vacation rentals in Adriatic Coast, Emilia Romagna sea holiday Italy. Promotion -20%
Great special offers for summer holidays, Italy - Lido di Spina and Lido degli Estensi accommodations for rent PROMOTION -20% -20% for stays of two weeks holiday for the arrivals o ...
Periodo: 22-11-2014 / 31-10-2015
Comacchio, Adriatic Coast , locations for Holidays in apartments and houses for rent in Lido degli Estensi and Lido di Spina. Lidi Ferraresi sea holiday, discounted price, -10%
Offers for sea holidays in Italy - summer holiday 2015 Accommodation in Adriatic Coast of Emilia Romagna with holiday home villas and apartments for rental in Lido di Spina - ...
Periodo: 22-11-2014 / 31-10-2015
Rentals apartments and houses for holiday in the Ferrara beaches. Promotions 9=7
Lido di Spina and Lido degli Estensi, Adriatic Coast, Emilia Romagna. Your holidays at sea Italy will be perfect, unforgettable and unique experience when you consider our offer: f ...
Periodo: 20-11-2014 / 31-10-2015
Special offer - 30%
Periodo: 02-12-2014 / 02-12-2015
Specials and Promotions 2014, seaholiday apartments for rent, special arrivals of September
VACATION RENTALS: PROMOTIONS & DISCOUNT 2014Lido di Spina, Lido degli Estensi, beaches of Ferrara Italy, on the beautiful Adriatic Coast of Emilia-Romagna, special promotions a ...
Periodo: 20-12-2013 / 21-12-2014
Ferrara beaches, sale of villas and apartments
Chalet for sale in Lido di Spina Adriatic Riviera of Emilia Romagna.
Lido di Spina villa for sale Lake neighborhood; property in beautiful building with 4 apartments in the Moorish style. Apartment all on the first floor; apartment with large living ...
Prezzo: 155000.00 €
Lido Spina, villa vendita zona Lago
Prezzo: 159000.00 €
Apartment for sale lido Spina, Comacchio
We sell apartment in residence with swimming pool; Apartments for sale on the Italian Adriatic coast Sale homes Adriatic Riviera Emilia Romagna, Lido di Spina ...
Prezzo: 85000.00 €
apartment for sale pineda, Lido di Spina, Adriatic Coast
Lido di Spina, Adriatic Coast, Apartment for sale,two bedrooms, living room, kitchen, bathroom, private garden ...
Prezzo: 125000.00 €
Lido degli Estensi, house for sale
Prezzo: 118000.00 €
Lido degli Estensi villa signorile
Prezzo: 230000.00 €
Lido Spina vendesi appartamento trilocale
Prezzo: 85000.00 €
Lido degli Estensi sale apartment
Prezzo: 105000.00 €
Lido di SPina, villino in vendita, vicino al mare
Prezzo: 149000.00 €
House business sale area Logonovo, Lido di Spina, Adriatic Coast
Lido di Spina, Adriatic Coast Emilia Romagna- Italy- sale house House on two levels in a small building with two private garden, located in the first part of Lido di S ...
Prezzo: 124000.00 €


text:
Thanks for redeeming.{{else}}
Success! Thanks for repurchasing.{{/if}} {{else}} {{#if Expired}}
Increase my visibility!{{else}} {{#if IsMultiPack}}
{{#if HasMultiPack}} You have {{MultiPackCount}} top spot(s) left. Now loading you into the search listings... {{else}} You have used all top spots. Now loading you into the search listings... {{/if}}{{else}}
We are loading you into the search listing pages...{{/if}} {{/if}} {{/if}} {{/if}}
{{Current}} just saw you!{{/if}} {{#if LastTopSpotPurchaseIsMulti }} {{#if HasAnyTopSpot}}
{{#if HasFreeTopSpot }} {{ UnclaimedTopSpotFree }} Free {{/if}} {{#if HasPaidTopSpot }} {{#if HasFreeTopSpot }} & {{/if}} {{ MultiPackCount }} {{/if}} Top Spot{{#if Plural}}s{{/if}} Left{{else}}
0 Top Spot{{#if Plural}}s{{/if}} Left{{/if}} {{else}} {{#if HasFreeTopSpot }}
{{ UnclaimedTopSpotFree }} Top Spot{{#if Plural}}s{{/if}} Left{{/if}} {{/if}} {{else}} {{#if HasResults}}
{{Current}} see you now!{{else}} {{/if}} {{/if}}
You can now invite anyone to meet at your favorite Starbucks.
Limited-time feature
33 year old woman | East Elmhurst, NY, USA | Seeking men 30-45 within 50 miles
Looking to meet new and interesting people :)
I decided to try match because like most people on here, it is difficult to meet new people to date when you are so busy working and living a full life. Eventhough working hard and having a successful career is important to me, just as important is having someone to share the success. Family is very important to me as well. I want to meet a man who is intelligent, ambitious, funny and has a good heart. No one is perfect, but I strive to be my best, and I want to see that in the person I hope to develop a relationship with. Good chemistry and someone who is supportive is also ideal. Outside of work, I like to go running and going to the gym, enjoy volunteering at local food banks and mentoring/tutoring, catch up on my DVR shows, and I love to shop :) Also, I visit the MoMa and Met museums often to see what the latest exhibits are and enjoy meeting up with friends for drinks in the city. Though I travel often for work, I still love to travel internationally, and I am hoping to visit Prague next. Basically, I am up for anything fun, as long as I have good company. Just looking for my partner in crime :) Honesty and loyalty are very important characteristics I look for in a man as well ...happy hunting!
Cooking , Dining out , Movies/Videos , Museums and art , Music and concerts , Exploring new areas , Nightclubs/Dancing , Performing arts , Playing sports , Political interests , Religion/Spiritual , Shopping/Antiques , Travel/Sightseeing , Volunteering , Watching sports
Basketball, Bowling, Dancing, Football, Running, Swimming, Tennis / Racquet sports, Walking / Hiking
I exercise 3-4 times per week.
Don't display my sign
Middle of the Road
I have been blessed to have had the opportunity to travel to many places...but I would love to return to the island Mykonos in Greece or Paris. I think it is the most beautiful place on earth. Traveling to the Carribean Europe is also a favorite.
As typical as this may sound, I love to go shopping....visiting Bliss spa and getting my weekly pedicure. I also love to go out with friends dancing, to the movies, the theatre, or whatever is on the agenda. Anything to have a good time..
I'm the type of person who will have fun doing pretty much anything as long as I'm with people I enjoy. Lately cooking has been #1 on my list. I'm hooked on the Food channel. I also enjoy going to the movies,the theatre, the met & MoMa
The WSJ. I also enjoy reading on a variety of topics but lately my favorite is on Latin American history and politics.
Z{{Cta}} {{#if HasMoreInfo}} ?{{CtaSecondary}} {{/if}}
|What she is looking for
|5'7" (170cms)
|6'0" (182cms) to 8'11" (271cms)
|Body type:
|Athletic and toned
|Slender, About average, Athletic and toned, A few extra pounds, Stocky
|Black, Blue, Brown, Grey, Green, Hazel
|Black, Light brown, Dark brown, Blonde, Dark blonde, Grey, Bald
|No Way
|No Way, Occasionally, Daily, Cigar aficionado, Yes, but trying to quit
|Social Drinker
|Social Drinker, Regularly, Moderately
|Medical / Dental / Veterinary / Fitness
|No preference
|I'll tell you later
|$75,001 to $100,000, $100,001 to $150,000, $150,001+
|Never Married
|Never Married, Widow / Widower, Divorced
|Have kids:
|Yes, and they sometimes live at home, No, Yes, and they live away from home, Yes, and they live at home
|Wants kids:
|Definitely, Someday
|Latino / Hispanic
|Black / African descent, Latino / Hispanic, White / Caucasian, Other
I was born and raised in NYC :)
|Christian / Catholic
|Christian / Catholic, Christian / Protestant, Jewish, Spiritual but not religious
|English, Spanish
|Bachelors degree
|Some college, Associates degree, Bachelors degree, Graduate degree, PhD / Post Doctoral
I graduated as an Electrical and Computer Engineer


text:
MTMC assignment up front: Canadian officer spurs shipments to his mates in Afghanistan.
Two hours after he drove away from his job at MTMC's Joint Traffic Management Office to a new assignment at the U.S. Air Force Base, Pelletier found himself on the cutting edge of the global logistical effort supporting the War on Terrorism.
Since Pelletier left MTMC on Feb. 26, and drove across the springtime land of Maryland and Delaware, the exchange officer has carved out a piece of history in a massive joint logistical effort between the United States and Canada. He has led a small team of soldiers supplying Canadian troops in Kandahar, Afghanistan.
For the first time, Canadians are using the Canada-United States Integrated Lines of Communication Agreement. The agreement provides for the use of American planes and ships to provide the logistical support for Canadians involved in a joint military action with the United States military.
"This has truly been one of the most exciting assignments in my two decades in the Canadian military," said Pelletier. "It's a great feeling knowing that our team directly impacts the welfare of our troops at the front."
"We've been getting great support from the folks at the 436th Aerial Port Squadron and thanks to them we've been able to support our troops in Kandahar."
For the Canadian Army, Pelletier was a logical choice to command his country's four-member team.
As a captain during Operation Desert Storm in 1990, he served at MTMC's Eastern Area Command, in Bayonne, N.J. Later in his career in 2000, he was reassigned to MTMC's Headquarters, in Alexandria, Va.
"I know the American acronyms and process," said Pelletier. "I can translate the Canadian requirements into something that the U.S. Air Force can understand."
The team's work represents "a complete success story," said Lt. Col. Michael Bergeron, Logistics Chief of the Canadian Forces Joint Task Force South West Asia, co-located with the U.S. Central Command, MacDill Air Force Base, Fla.
"They were able to get material moving on American planes to the Arabian Gulf area and Afghanistan within two weeks of hitting the ground," said Bergeron. "That is quite a feat considering the steep learning curve they were facing and considering it had never been done before."
Originally designed to support a NATO conflict in Europe, the agreement's mandate was widened after the Gulf War to cover any operation in which both countries participate anywhere in the world.
"The agreement is unique," said Lt. Col. Jean-Pierre Pichette, Canada's senior representative to the agreement, who is currently serving at the U.S. Transportation Command, Scott Air Force Base, Ill. "It is a bilateral agreement between two partner nations which, when activated, blends the entire North American transportation infrastructure and resources into a single system."
This is also Pichette's second tour as a Canada-United States Integrated Lines of Communication Agreement officer. He worked with the agreement in the mid-1980s while assigned in Ramstein, Germany, with the U.S. Air Force Europe.
"It is activated by mutual consent," said Pichette. "It was activated for the very first time on December 5, 2001. We are now reaping the benefits of the more than 20 years we have invested in the agreement moving a steady flow of cargo to support our troops half way around the world. We are making logistics history and are setting the way for the future."
There is a key difference between the agreement and the Cooperative Airlift Agreement, said Maj. Sylvain Turbide, a Canadian officer assigned to the Air Mobility Command.
"Under the Canada-United States Integrated Lines of Communication Agreement, Canada can ship cargo on American planes according to its priority," said Turbide. "The cargo moves according to its priority, so the highest priority cargo leaves on the next plane--the country of ownership of the cargo and the aircraft do not come into play at all."
The Cooperative Airlift Agreement only allows shipment on a space available basis.
The Canada-United States Integrated Lines of Communication Agreement enables Canada to take advantage of the vast American transportation resources to better support our troops deployed on operations, said Pichette.
The agreement is not only for the movement of freight, said Maj. Phyllis O'Grady, a Canadian officer assigned to the Command Surgeon's Office at U.S. Transportation Command.
"There is a health care side to it," said O'Grady. "It can also be used to transport our sick or injured troops from the area of operation back to North America."
Currently, there are three American flights from Dover Air Force Base to the Arabian Gulf Region where the Canadian logistics group supporting its troops in Kandahar is located. The flights represent an air bridge for Canadian forces, said members of Pelletier's team.
"We have been shipping material on every flight since March 19," said Warrant Officer Mike Forrest, of 1 Air Movements Squadron, Winnipeg, Canada.
"The cargo destined for the Arabian Gulf region is shipped to us from Montreal," said Sgt. George Lake, a loadmaster with 435 Transport & Rescue Squadron, Winnipeg, Canada.
"Then we input it into the American system."
The fourth member of the team, Cpl. Mick Toutant, of 1 Air Movements Squadron, agreed on the high quality of American cooperation.
"The folks here have been extremely friendly and have taught us to use the American Air Forces system," said Toutant.
"We make a great team!"
Reader Opinion
|Printer friendly Cite/link Email Feedback
|Article Type:
|Brief Article
|May 1, 2002
|Previous Article:
|Surface shipments sustain troops in Afghanistan.
|Next Article:
|Record LMSR load sails from Charleston.


text:
This database provides information on environmentally related taxes, fees and charges, tradable permit systems, deposit refund systems, environmentally motivated subsidies and voluntary approaches used in environmental policy in OECD member countries and a number of other countries. Developed in co-operation between the OECD and the European Environment Agency.
By participating more effectively in the global production of goods and services, Africa can transform its economy and achieve a development breakthrough, according to the latest African Economic Outlook, released at the African Development Bank Group's Annual Meetings.
South Africa must take urgent steps to proactively investigate and prosecute foreign bribery. No foreign bribery cases have been prosecuted since South Africa joined the Convention in 2007. The 4 on-going investigations – out of only 10 allegations that have surfaced to date – are also far from reaching the prosecution stage, according to a new report by the OECD Working Group on Bribery.
This page contains all information relating to implementation of the OECD Anti-Bribery Convention in South Africa.
South Africa has experienced a relatively weak recovery from the great economic crisis compared to other BRIICS countries.
These statistics set out industrial production of total industry, manufacturing, manufactured crude steel, manufactured intermediate and investment goods, energy, construction. The series are updated continuously and are shown as seasonally adjusted indices. The series are updated continuously.
Source: OECD Main Economic Indicators (updated continuously) - Composite leading indicators (CLIs) are calculated for 29 OECD countries (Iceland is not included), 6 non-member economies and 9 zone aggregates. A country CLI comprises a set of component series selected from a wide range of key short-term economic indicators mainly covered in the MEI database.
OECD Secretary-General, Angel Gurría, said that it was with a heavy heart and a debt of gratitude that the world was bidding farewell to Nelson Mandela.
The world badly needs great leaders. The tragedy of Mandela's passing is that it underlines the rarity of his extraordinary combination of courage, commitment, charisma, intelligence, self-sacrifice and, rarest of all, wisdom.
In its first Environmental Performance Review of South Africa, the OECD praises the progress made with environmental reforms. It also urges Africa's biggest economy to keep focusing on green growth to help it shift towards a low-carbon model that will improve the well-being of all South Africans and preserve its rich natural habitat.


text:
Absorbing Reads for Middle Graders These new novels for 4th- through 7th-graders feature lions, aliens, a Bronze Age adventure, a boy who sets out to save his sister's life and the environment, and a heartwarming tale of a homeless girl. "Feral Pride" by Cynthia Leitich Smith; …Read more. Pet Tales To Please These funny new books star a rambunctious bunch of pets sure to make children laugh and then want to read more. "Dogs Are People, Too" by Dave Coverly; Henry Holt; 214 pages; $12.99. "A Collection of Cartoons To Make Your Tail Wag," as it's …Read more. Rock and Relax with These New CDs Music made for children has evolved dramatically in the past 10 years. With high-quality music just as lush and well-produced as adult tunes, this gamut of new CDs is well worth a listen. All are, or soon will be, available at such outlets as iTunes …Read more. Books for Clever Teen Girls Young adult fiction has come a long way in the past 10 years, mostly due to the sheer volume of intriguing, fun and smart novels and the popularity of teen reading. These are a few of the most promising reads aimed at girls. "The Perfectionists" by …Read more.more articles
Wintry Holiday Tales
Though still a tad early in my own mind, these wintry tales should get young readers in the holiday mood.
With these new gift selections, kids can create their own Christmas story with festive cards, watch Caldecott award-winning tales on DVD and escape to Italy with the latest Strega Nona tale from Tomie dePaola.
"StoryWorld: Create-a-Story Kit: Christmas Tales" by John & Caitlin Matthews; Templar Books/Candlewick Press; $9.99.
The innovative StoryWorld kits are the size of chapter books and include a small idea-filled storytelling book and a sturdy set of 28 cards. The cards feature people, places and other story ideas centering on a Christmas theme; in this case, a magical, Old World holiday feel. With the book, the set encourages kids to write, draw, act out and imagine umpteen stories and games.
A smart way to help kids, parents and teachers unlock their imaginations, "StoryWorld" sets make lovely gifts. Others include "Fairy Magic," "Legends of the Sea" and "Tales from the Haunted House." The sets are also perfectly sized for stocking stuffing.
"Caldecott Favorites Featuring The Snowy Day" from Scholastic Storybook Treasures; $17.99.
The high-quality Scholastic Storybook Treasures DVD series features award-winning children's books captured on video, with read-along features and a timeless, quiet appeal. This set includes Caldecott award-winning favorites, from Ezra Jack Keats' "The Snowy Day" to "Make Way for Ducklings," "The Ugly Duckling" and "In the Small, Small Pond." Twenty stories in all on three DVDs aim to promote "honesty, humor and respect," and run over three hours.
And though too late for Thanksgiving viewing, the reminder to be thankful and to honor those who came before us is always important. Also from Scholastic Storybook, "Giving Thanks" tells four award winning stories, with the titled tale, plus "Hiawatha," "The Pilgrims of Plimoth" and "Lincoln and Douglass: An American Friendship" to celebrate history and Native American heritage.
"The Snowy Day: 50th Anniversary Edition" by Ezra Jack Keats; Viking/Penguin; 40 pages; $19.99.
In 1962, this tale of a little boy in a snowsuit changed the face of children's literature with its portrayal of an African-American child and beautifully innovative collage artwork.
A beautiful presentation of a wondrously magical, simple winter tale, "The Snowy Day" remains one of the most beloved tales in children's literature.
"Strega Nona's Gift" by Tomie dePaola; Nancy Paulsen Books/Penguin; 32 pages; $17.99.
The prolific Tomie dePaola's Caldecott Honor Award winner, "Strega Nona," captured the love, warmth and joy of growing up in a delicious Italian family. His newest release stars Grandmother Strega Nona and Big Anthony as they cook for and celebrate eight feasts during their Italian village's holiday pageant. Hilarity and animal-themed adventure ensue with a series of mishaps bound to make kids giggle.
A heartwarming holiday story, "Strega Nona's Gift" introduces young readers to fun Italian phrases and customs and is a smart choice for not only Christmastime, but also for welcoming in a New Year, and for exploring new traditions.
"Hansel & Gretel" by Susan Jeffers, the Brothers Grimm and Amy Ehrlich; Dutton/Penguin; 32 pages; $17.99.
Enchantingly retold by Amy Ehrlich, this timeless Grimm fairytale is presented here for younger children, with deliciously non-scary, but detailed, illustrations from Susan Jeffers. Full of familial love and the classic appeal of true fairy tales, this "Hansel & Gretel" includes lots of friendly gingerbread people, colorful gumdrops and hopping bunnies. The story, however, remains basically true to the original, and the witch is still pushed into the stove before the relieved brother and sister escape to find their father's house.
A fabulously entertaining read-aloud for children who can handle a tale, which ends with the ramifications of good versus evil, Jeffers' scenic tale is scrumptious.
To find out more about Lee Littlewood and read features by other Creators Syndicate writers and cartoonists, visit the Creators Syndicate website at www.creators.com.


text:
SALADO, Texas (AP) — Emergency crews are responding to a reported bridge collapse along an interstate in Central Texas.
If you just have to have it now, as in one hour, you can, at least in the Dallas area, as Amazon.com Inc. announced Thursday it will offer Prime Now.
The future of a redevelopment plan for the 50-year-old Westchester Plaza on Fort Worth's Near Southside is unclear.
Texas unemployment fell to 4.3 percent during February for the sixth straight month of declines, the Texas Workforce Commission reported Friday.
Monty Bennett's name will not appear on the ballot for the Tarrant Regional Water District board of directors yet he remains a powerful backstage player whose influence could shape the direction of the district's business for years to come.
PETER SVENSSON,AP Technology Writer
NEW YORK (AP) — AT&T Inc. is launching its home security and automation service in 15 cities Friday, with an eye toward getting customers hooked on security cameras, thermostats and locks they can control from phones and tablets.
AT&T's "Digital Life" packages will be sold in cellphone stores in markets including Los Angeles, Chicago, San Francisco and Miami. The company plans to roll the offering out to 50 markets by the end of the year.
The home monitoring and automation field is dominated by security firms such as ADT Corp. Other phone and cable companies sell security packages, but AT&T is going further than competitors by developing its own technology and selling it nationwide, not just where it provides local phone service. It has set up monitoring centers, in Dallas and Atlanta.
The entire U.S. home security market is worth about $18 billion per year, said Glenn Lurie, who is in charge of expanding the reach of AT&T's network to new types of devices. That's small compared to AT&T's $127 billion in annual revenue. But only 20 percent of homes have security systems, so there's an opportunity to expand the market, Lurie said.
The initiative comes as the wireless industry has slowed after a decade of heady growth. Now that nearly everyone has a cellphone, wireless companies are looking for other sources of growth.
"We see huge opportunity here. This is a significant, billion-dollar opportunity for AT&T," Lurie said.
AT&T is also hoping to get customers to pay more than the typical $40 per month for home security alone, by providing connections to wireless cameras and other sensors.
AT&T will charge $250 for the equipment and installation of a home security package, plus $40 per month. Options include a camera package for $10 per month plus equipment and installation, climate control for $5 per month, and a remote water main shutoff control for $10 per month.
The equipment ties into a central control panel which can be programmed through the app or Web interface to, for instance, shut off the water main if the water sensor detects a leak.
A basic, security-only package will cost $150, plus $30 per month.
Ralph De La Vega, head of AT&T's wireless division, said employees who tested Digital Life in Atlanta and Dallas last year bought a lot more cameras than the company had been expecting. One of them set a camera to be triggered by motion sensor on the front porch, and nabbed a thief who had been stealing packages.
Only about 1 percent of homes have automation systems, and De La Vega said this could be a big opportunity as well. He's happy he can now check whether his garage doors are open and close them from his phone.
"It's just getting people used to living a different way ... We haven't even begun to tap into the available marketplace. I think the idea is huge," De La Vega said.
The central panel connects to AT&T's wireless network, but should also be connected to a wired Internet modem for redundancy, AT&T said. Any Internet connection will work — it doesn't have to be AT&T's.
Two years ago, AT&T bought Xanboo, a smart-home technology startup. Last year, AT&T announced its plans to launch Digital Life nationwide, and ran trials with employees in Dallas and Atlanta.
< back


text:
Related Products
Audio Assault has released KlipFreak, a free clipper plug-in for Mac OS X and Windows in AU, RTAS and VST plug-in formats.
Head over to audio-assault.com to download.
Discussion: Active
Please log in to join the discussion
Related news...
Audio Assault News
Other Related News
23 Mar 2015 Audio Assault updates XCTR Harmonic Exciter to v1.0.116 Mar 2015 Audio Assault updates free Klipfreak plugin for Mac & Win to v1.0.107 Mar 2015 #KVRDeal Expired Get the full Audio Assault Bundle for $99.9902 Mar 2015 Audio Assault releases XCTR Harmonic Exciter for Windows and OS X26 Jan 2015 Audio Assault Updates Head Crusher to 1.212 Jan 2015 Audio Assault Updates Multi Transient to 1.0122 Dec 2014 Audio Assault Releases FreaQ Analog Style Equalizer03 Dec 2014 #KVRDeal Expired Audio Assault offers Bass Grinder for Free with purchase of Grind Machine24 Nov 2014 Audio Assault releases "Multi Transient" envelope shaper plugin for Mac & Win (and updates free Transient plugin)10 Nov 2014 Audio Assault updates HeadCrusher Saturation Plugin to v1.103 Nov 2014 Audio Assault releases Transient - Free Transient Shaping Plug-in for Mac & Win VST, AU, RTAS & AAX25 Aug 2014 Audio Assault releases "HeadCrusher" Saturation Plug-in for Mac and PC11 Aug 2014 #KVRDeal Expired Audio Assault offers GrindMachine/BassGrinder Metal Amp & Bass Sims for $19.99 each28 Jul 2014 Audio Assault Updates GrindMachine to 1.55 - New Amps & Cabs23 Jun 2014 Audio Assault releases GrindMachine AAX/VST3 for OS X and Windows09 Jun 2014 Audio Assault releases BassGrinder AAX for OS X and Windows30 May 2014 Audio Assault releases KlipFreak - Free Clipper Plug-in for Mac & Win VST, AU & RTAS17 May 2014 AudioAssault releases BassGrinder - Bass Guitar Amps


text:
product details-Tab
Promotes Efficient Plunging: The Plunger Flange Has a Long & Narrow Profile Specially Designed to Work More Efficiently with Modern Toilets
We've designed a plunger that doesn't leave drips behind. A unique magnetic collar helps secure the cover to the plunger so you can carry them together — without a single drip hitting the floor. The dome shaped cover discreetly hides the plunger, while the large opening at the back helps make the plunger easy to access. The plunger itself is specially designed with a narrow profile to work more efficiently with modern toilets.
Made in China


text:
Not Exactly a Golden Age
NOTE: This review was originally posted on my blog, Cartridge Campus.
After a six-year hiatus and a changing of the guard, Age of Empires is back with a new look and a new focus. Gas Powered Games and Robot Entertainment have attempted to capture the the robust strategy and enthralling combat that their predecessors pioneered, while adding in new, online-specific additions. There's a lot to like in this gorgeous revival, but gigantic pay-walls and shoddy Player vs. Player content strive to ruin the whole experience.
The Excellent:
- Easy to Learn...: Whether you're a greenhorn or an experienced real-time-strategist, you'll feel right at home in a manner of minutes. The game teaches you one concept at a time at a pace that's forgiving, yet wastes little of your time. The world would be a better place if this sort of standard was applied to the average AAA title.
- ...Hard to Master: When the training wheels come off, you'll be more than ready to take on the world. That's a good thing, because the world will certainly have it in for you. Every quest brings a new, unique scenario; you'll find yourself performing all sorts of tasks, from escorting villagers through treacherous roads to protecting a town from an onslaught of enemies. The A.I. is quick and merciless, breaking down all but the best defenses. You'll occasionally find yourself crawling to the finish by your teeth, and even when you do fail, it feels completely justified. Once you're on a roll, completing quests left and right, it's hard to stop.
- AAA Presentation: For a game targeted at the "Free to Play" crowd, the presentation of the game is practically unparalleled. The cartoonish art style is unique and easy on the eyes, even on the lowest graphical settings. The visual polish also extends to the user interface, placing every possible option and action in an easily digestible format. Developers, take notes; this is how you properly present your game.
- AOE Veterans Welcome: If you've played an Age of Empires game before, you'll feel right at home here. The same complexity and breadth of options you grew up with are still at your fingertips. You'll still be gathering resources, fortifying your base camps, and laying waste to your enemies with the right-click of the mouse. And yes, Loom still gives your villagers 50% more health. Even though the tutorials are more frequent and it's somewhat easier to manage your army, make no mistake; it's still built with you in mind. Nothing's standing between you and your game (except for one large issue, which we'll get into later).
- With a Dash of WoW: Gas Powered Games and Robot Entertainment have done the impossible; they've successfully merged MMO elements into an RTS. Missions are now presented as quests, with rewards of experience and items upon successful completion. As you level up, you'll get points to dump into a technology tree, which gives you benefits like stronger houses or new units to play with. The items also serve a purpose; equipment can be earned and assigned to units and buildings, giving your soldier or villager an extra edge in their activities.
Unfortunately, the MMO elements are also what leads us into our next section:
The Horrible:
- Pay to Play: Once you've invested several hours into the game, you're getting into the swing of things. Fantastic weapons are finding their way into your inventory, enemies are trembling at your feet, and you're receiving blueprints to make your civilization a much stronger, lovelier place. Just when you think you've got it all, your luck turns south. Your inventory is too small to store all the items being thrown at you. The weapons you obtain from your epic conquests now come with locks, rendering them useless and taking up your valuable storage. Your enemies are even rougher and tougher than they were 5 minutes ago, and even your strongest defenses are failing miserably. That's when you discover the game's dark secret; all of your troubles could be rectified if you only spent $20 on your civilization. $20 isn't the worst, but it's also not "Free to Play". The "free" version starts feeling like a demo. And it gets worse...
- Highway Robbery: As you make your way to the store, $20 clutched firmly in your hand, you decide you might as well check out what else they have to offer while you're here. Oh, look, they have a sale on two civilization packs and extra missions for... $40? Maybe you should buy the season pass instead, so you really get a value! ...$100 DOLLARS? The point of a "Free to Play" game is to have micro transactions. Maybe Microsoft, Gas Powered Games and Robot Entertainment should get together, crowd around a dictionary and look up the definition of "micro". It means "small". $100 is not "small".
- Not Even Worth It: If the content justified the price, the $20 wouldn't be a monumental loss. Unfortunately, the only real bonus you get from dropping a Jackson on the game involves taking off all the restrictions. You get a bigger inventory, you can build more stuff, and you get those extra slots in the technology tree. Maybe it wouldn't feel like such a bad deal if the included PvP combat, the heart and soul of most RTS titles, worked properly, but even that falls flat. Network issues abound, from disconnects to serious latency problems. Even the matchmaking itself feels busted. You'll often find yourself grouped up against an opponent who can easily wipe the floor with you. Even though the game accurately keeps leaderboards, it doesn't put that knowledge to good use and set you up with a worthy opponent. It's flat-out disappointing, and it's almost enough to sour the entire game.
While the game certainly is captivating for the first few hours, Age of Empires Online eventually chokes all the fun out of the experience by charging ludicrous amounts of money for sub-par bonuses and content. The game bits more than live up to the legacy of the series; everything else seeks to cut up the pie and charge you heavily for each piece. It's a shame that such a beautiful, polished product has been put to waste. Spend your time (and your money) elsewhere.
Verdict: Skip It


text:
ALDO Sale | Malaysia Sale
Summary: ALDO Malaysia Sale. Discount up to 70% off on selected styles.
Company: ALDO
Sales: 22nd Jan 2010 till 4th Feb 2010
Venue: ALDO, Isetan KLCC, Ground floor, Kuala Lumpur, Wilayah Persekutuan.
For those who are unable to visit the sale promotion events or looking for others products discounts offers in Malaysia, you could also find some great discounts offers thru Malaysia Great Deals at the link:
Previous Sale
Next Sale
Filed Under: Malaysia Sales • Promotions & Freebies


text:
Prabhas Rebel Movie Photos
June 6th, 2012, 04:40 PM IST
From Politics
- Telugu Guinness Record Holder Missing
- Captain's Touching Letter To Indian Fans
- Saina Nehwal, The World No.1 Badminton Player
- Pic Talk: Virat & Anushka Walk Hand In Hand
- Star Hero Requests Ban On Media
- TATA raises Funds towards Mission Kakatiya
- Son Beats Parents To Death For Betting Money
- RGV Trolled By Former Chief Minister
- Kohli's Not The Reason For Our Loss - Dhoni
- Vajpayee To Receive Bharat Ratna Today
Latest Movie News
- Telangana-MAA's Advise To Manchu Lakshmi
- What Has Nagababu Done At MAA?
- It's Half Century For Superstar!!!
- Mahesh Will Soar It To New Heights
- Teaser Talk: Chay's Energetic Intro Song
- Bollywood beauty unveils her wax statue
- Tamanna Turns Brand Ambassador For TV channel
- Ganesh Wants To Give 1hr Speech At Mega Event
- Allu Arjun Picked Hard Rock Cafe
- Poonam's Massage Video For Sri Rama Navami


text:
Discover a selection of top forums lyrics there on the internet. Come to share your passion on forums lyrics there and meet other fans of lyrics there. Then, why don't you create your own forum of lyrics there ?
Free forum : Forum for Friends
delishus, star, singer, sangeetham, music, super, season4, season, asianet, kairali, amritha, sangeetha, sallapm, indian, idol, songs, #lyrics, shows, programms, sangamam
Foro dedicado a la cantante japonesa Koda Kumi.
love, koda, kumi, foro, blog, cantante, noticias, news, ニュース, videos, videoclips, comerciales, anuncios, imagenes, images, photos, fotos, 画像, letras, #lyrics, 歌詞, traducciones, lives, forum, performances
a platform to bring writers together in order to organize and decipher their individual voices. A writing forum? Sure, you can find a lot of different writing forums online and from around the world. What makes Scribbles unique is their diversity, we
forum, poets, writers, readers, reviews, artists, songwritings, poetry, poems, books, fiction, nonfiction, verses, #lyrics
The first Italian Satsuki's Worldwide Fan Community Online
satsukimania, 砂月, forum, translation, moon, stream, international, support, italy, satsuki, italian, news, #lyrics, blog, ameblo, ameba, pictures, awake, crystal, spiral, jrock


text:
: [Tool]
Cry Pointer Repointer
View Single Post
February 5th, 2011 (12:54 AM).
Advanced Trainer
Join Date: May 2010
Thanks, but when I put in table info and dex number and hit samples, I get Error: File not found. It seems pokecry doesn't recognise my Fire Red. I tried an unedited version of Fire Red to see if my ROM was bad, but pokecry won't recognise any pokemon ROM, not even fresh ones that haven't had anything done to them.
I'm sorry for asking in your thread. I was told to use Cry Pointer Repointer. Now I don't know why pokecry won't work at all. I'll go ask around again.
View Public Profile
Send a private message to Beechlgz
Find all posts by Beechlgz
Find threads started by Beechlgz
Ignore Posts by Beechlgz


text:
The weight of books
In the real world, my new floor-to-ceiling shelves are already full and bulging, and lately I wander the house eyeballing the last remaining bits of open wall space, wondering if they might hold additional shelving, as my wife shakes her head.
"For what else," Benjamin writes of his own books, "is this collection but a disorder to which habit has accommodated itself to such an extent that it can appear as order?" My wife would heartily agree. And yet, the order Benjamin invokes is hardly an illusion, but rather a way to find myself in all those shelves and volumes, an assertion, a means of saying: I am here.